Revelation Biosciences, Inc. · NASDAQ:REVB
Revelation Biosciences — Investor Presentation (May 2023)
27 slides from Revelation Biosciences's investor presentation, May 25, 2023
Slide 1: Corporate Presentation May 2023
Developing innovative therapeutics to address unmet needs Corporate Presentation / May 2023 www.revbiosciences.com
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These forward-looking statements are generally identified by the w
Slide 3: PHAD-Based Therapeutic Development Pipeline
PHAD-Based Therapeutic Development Pipeline Revelation has a pipeline of potential high-value products based on the activity of PHAD Revelation has developed proprietary formulations and methods of use to deliver phosphorylated hexaacyl disaccharide (PHAD®) systemically or locally to treat various d
Slide 4: PHAD is a Well-Defined TLR4 Agonist with Multiple Potential Applications
Cytokine induction PHAD is a Well-Defined TLR4 Agonist with Multiple Potential Applications REVTx-300 Program Treatment of acute and chronic inflammatory disease AKI CKD Myocarditis PHAD Redirection of Innate Immune Response REVTx-100 Program Prevention and treatment of healthcare associated infecti
Slide 5: REVTx-300 For the Treatment of Acute and Chronic Kidney Diseases
REVTx-300 For the Treatment of Acute and Chronic Kidney Diseases
Slide 6: REVTx-300 Program Highlights
REVTx-300 Program Highlights 1. Zwirner, N. and Ziblat, A. 2017 doi: 10.3389/fimmu.2017.00025 2. Ismaeli, J. et. al. 2022 doi: 10.4049/jimmunol.168.2.926 3. Hernandez, A. et. al. 2019 DOI: 10.1097/CCM.0000000000003967 4. Revelation Data Chronic and acute organ disease (AKI, CKD, NASH, and myocarditi
Slide 7: PHAD Pretreatment Reduces AKI in a Unilateral Ischemia/Reperfusion Model
PHAD Pretreatment Reduces AKI in a Unilateral Ischemia/Reperfusion Model 1. Hernandez A, Patil N, et. al. Pretreatment with a novel Toll-like receptor 4 agonist attenuates renal ischemia-reperfusion injury. American Journal of Physiology-Renal Physiology 2023 324:5, F472-F482 Mice pretreated with in
Slide 8: PHAD Pretreatment Reduces AKI in a Bilateral Ischemia/Reperfusion Model
PHAD Pretreatment Reduces AKI in a Bilateral Ischemia/Reperfusion Model1 1. Hernandez A, Patil N, et. al. Pretreatment with a novel Toll-like receptor 4 agonist attenuates renal ischemia-reperfusion injury. American Journal of Physiology-Renal Physiology 2023 324:5, F472-F482 Mice were pretreated wi
Slide 9: PHAD Treatment Reduces Fibrosis in Acute and Chronic Kidney Model
PHAD Treatment Reduces Fibrosis in Acute and Chronic Kidney Model (UUO in Rats) Composite data represents the average of 3 anatomically distinct depths (10 images / depth / rat / group = ~60-65% of renal cortical area) Renal cortical fibrosis, expressed as Collagen Volume Fraction (CVF; via quantita
Slide 10: PHAD Antifibrotic Effects Likely Mediated by Validated Target Cytokines
PHAD Antifibrotic Effects Likely Mediated by Validated Target Cytokines TGF-β is pro-fibrotic and is directly linked to the propagation of fibrosis1,2,3,4 IL-10 is a key driver for the reduction and resolution of inflammation NGAL is an important defense for preventing excessive oxidative damage res
Slide 11: AKI Epidemiology
AKI Epidemiology In the US, 1% of all hospital admissions have AKI on admission1 During hospitalization, the approximate incidence rate of acute kidney injury is 2 to 5% and it develops in up to 67% of patients admitted in the intensive care unit1 AKI is an important contributor to increased hospita
Slide 12: AKI as a Result of Cardiac Surgery
AKI as a Result of Cardiac Surgery DOI: 10.2147/IJNRD.S167477 DOI: 10.1097/ACO.0000000000000422 DOI: 10.214470/1678-9741-2018-0084 Up to 31% Of patients undergoing cardiac surgery with no prior CKD develop post operative AKI3 50% Death rate of patients that develop post operative AKI2 $42.6k Average
Slide 13: Total US Addressable Market for REVTx-300 is over 42M Annual Potential Patients
Total US Addressable Market for REVTx-300 is over 42M Annual Potential Patients Our initial strategy will be to seek approval for prevention of AKI following surgery. Initial clinical studies will enroll patients undergoing cardiac surgery. Conservatively, if we treat 20% of the cardiac surgery AKI
Slide 14: REVTx-300 Development Plan
REVTx-300 Development Plan Phase Indication Anticipated Timing Use of Data Preclinical AKI (I/R) 2023 Support IND Preclinical Other 2023 Support additional indication Phase 1a Healthy volunteer 2023 Support Phase 1b study for REVTx-100 and REVTx-300 Phase 1b AKI1 2024 Support Phase 2 study Phase 2 A
Slide 15: REVTx-300 Phase 1a/1b Draft Clinical Study Design
REVTx-300 Phase 1a/1b Draft Clinical Study Design Planned for 2023 6 cohorts/8 subjects per cohort randomized 1:4 placebo vs drug: Phase 1a: Health volunteers1 Phase 1b: Patients undergoing elective cardiac surgery 30 subjects randomized 1:1:1 placebo: low dose group: high dose group Single ascendin
Slide 16: REVTx-100 For the Prevention of Healthcare Associated Infection
REVTx-100 For the Prevention of Healthcare Associated Infection
Slide 17: REVTx-100 Program Highlights
REVTx-100 Program Highlights Scientific Rationale 1. 2015 HAI and Antibiotic Use Prevalence Survey, CDC.gov Stimulation of TLR4 via the TRIF pathway with REVTx-100: Augments immune cell recruitment, which increases pathogen clearance Downregulates the pro-inflammatory response, reducing cellular dam
Slide 18: Pretreatment with PHADs Impart Protection from Gram Negative Bacterial Infection
Pretreatment with PHADs Impart Protection from Gram Negative Bacterial Infection Hernandez, et. al. Phosphorylated Hexa-Acyl Disaccharides Augment Host Resistance Against Common Nosocomial Pathogens. DOI: 10.1097/CCM.0000000000003967 Study Design: Mice were pre-treated (24 and 48 hours) with vehicle
Slide 19: Pretreatment with PHADs Impart Protection from Gram Positive Bacterial Infection
Study Design: Mice were pre-treated (24 and 48 hours) with vehicle, MPLA (1 mg/kg), or PHADs (1 mg/kg) prior to infection with S. aureus. All given IV. Bacterial counts assessed 3 days post infection. n = 7 to 10 animals per group. Pre-treatment with MPLA and PHAD(s) demonstrated improved pathogen c
Slide 20: Reduction of Pro-inflammatory Biomarkers Supports the Underlying Mechanism of PHAD
Study Design: Mice received vehicle or 20 μg of LPS or 3D 6-Acyl PHAD via IP injection. Blood was harvested at 3 or 6 hours after treatment, processed for plasma extraction, and analyzed for cytokine concentrations. *p<0.05 compared to LPS. Results represent 2 separate experiments, n=5–10 per group.
Slide 21: The Impact of Surgical-Site Infections (SSI)
The Impact of Surgical-Site Infections (SSI) DOI:10.1001/jamasurg DOI:10.1086/676022 DOI: 10.1016/j.jamcollsurg.2016.10.029 ~€11bn represents the midpoint of the range discussed in WHO Global guidelines on the prevention of surgical site infection. Nov 2016 DOI: 10.1086/501572 Up to 30% Estimated SS
Slide 22: Total US Addressable Market for REVTx-100 is over 6.3M Annual Procedures
Total US Addressable Market for REVTx-100 is over 6.3M Annual Procedures Surgeries in Hospital-Based Ambulatory Surgery and Hospital Inpatient Settings, 2014 Claudia A. Steiner, M.D., M.P.H., Zeynal Karaca, Ph.D., Brian J. Moore, Ph.D., Melina C. Imshaug, M.P.H., and Gary Pickens, Ph.D. Confidential
Slide 23: REVTx-100 Program Development Plan
REVTx-100 Program Development Plan The REVTx-100 program has potential utility across multiple indications Revelation plans to develop REVTx-100 as a treatment for multiple indications through Phase 3 Potential for strategic license and/or partner for commercialization Phase Target Indication1 Antic
Slide 24: REVTx-100 Phase 1a/1b Draft Clinical Study Design
REVTx-100 Phase 1a/1b Draft Clinical Study Design 6 cohorts/8 subjects per cohort randomized 1:4 placebo vs drug: Phase 1a: Healthy volunteers1 Phase 1b: Patients undergoing elective abdominal colorectal surgery 30 subjects randomized 1:1:1 placebo: low dose group: high dose group Single ascending d
Slide 25: Financial Overview
> REVELATION Financial Overview ~ BAOESI@IIEINIGIESS
Slide 26: Management Holdings and Cap Table
Management holdings Percent George Tidmarsh, M.D., Ph.D. (Chairman) 2.0% All other management 0.8% Total management 2.8% Cap Table Shares Common Stock Outstanding 6,048,863 Class C common stock warrants w/$5.36 exercise 1,108,260 Public Warrants w/$402.50 exercise (REVBW) 300,332 Warrants w/$24.20 w
Slide 27: Thank you!
For more information please visit www.revbiosciences.com Thank you!
Revelation Biosciences — Investor Presentation (May 2023) on 6ix